Invesco NASDAQ Biotech UCITS ETF AccIndex, costs, backtest, listings and taxation

One email when new issuers, new metrics and new articles land. Double opt-in, zero spam, one-click unsubscribe.

Redemption and Dealing of Shares:The Fund's shares are listed on one or more Stock Exchange(s). Investors can buy or sell shares daily through an intermediary directly or on Stock Exchange(s) on which the shares are traded. In exceptional circumstances investors will be permitted to redeem their shares directly from the Umbrella Fund in accordance with the redemption procedures set out in the prospectus, subject to any applicable laws and relevant charges. Investment objective: The investment objective of the Fund is to achieve the total return performance of the NASDAQ Biotechnology Index (the "Index"), less fees, expenses and transaction costs. Investment approach: The Fund is a passively managed ETF. To achieve the objective the Fund will use unfunded swaps ("Swaps"). These Swaps are an agreement between the Fund and an approved counterparty to exchange one stream of cash flows against another stream but do not require the Fund to provide collateral, on the basis that the Fund has already invested in a basket of equities and equity related securities (namely shares). Please note that the Fund will purchase securities that are not contained in the Index. The performance of the Index is swapped from the counterparty to the Fund in exchange for the performance of equities and equity related securities held by the Fund. The Fund uses derivatives for investment purposes. The use of such instruments may impact the magnitude and frequency of the fluctuations in the value of the Fund. The Fund’s ability to track the Index performance is reliant on the counterparties to continuously deliver the performance of the Index in line with the swap agreements. The insolvency of any institutions acting as counterparty to derivatives or other instruments, may expose the Fund to financial loss. The Fund’s base currency is USD.

Keep reading the KID section ▾

Intended Retail InvestorThe Fund is intended for investors aiming for long term capital growth, who may not have specific financial expertise but are able to make an informed investment decision based on this document, the supplement, and the prospectus, have a risk appetite consistent with the risk indicator displayed below and understand that there is no capital guarantee or protection (100% of capital is at risk). Practical Information Fund Depositary: Northern Trust Fiduciary Services (Ireland) Limited, George’s Court, 54 – 62 Townsend Street, Dublin 2, Ireland Find out more: This document is specific to the Fund. Further information about the Fund can be obtained from the supplement, the prospectus, annual and interim reports. The prospectus, annual and interim reports are prepared for the Umbrella Fund, of which the Fund is a sub-fund. These documents are available free of charge in English. They can be obtained along with other information, such as share prices, at https://etf.invesco.com (select your country and navigate to the Documents section on the product page), or by calling +353 1 439 8000. The assets of the Fund are segregated as a matter of Irish law and as such, in Ireland, the assets of one sub-fund will not be available to satisfy the liabilities of another sub-fund. This position may be considered differently by the courts in jurisdictions outside of Ireland. Subject to satisfying certain criteria as set out in the prospectus, investors may be able to exchange their investment in the Fund for shares in another sub-fund of the Umbrella Fund which is being offered at that time. The Index: The Index is designed to represent the performance of biotechnology and pharmaceutical securities on the NASDAQ Stock Market. The Index is a modified market capitalisation weighted index. The securities eligible for inclusion include common stocks, ordinary shares, ADRs and shares of beneficial interest or limited partnership interests. The Index has approximately 116 components and is rebalanced on a quarterly

• Moneyfarmzero on single buys from 1,000 €, agreement until 31 December 2026
• XTBzero (up to €100,000 monthly volume, unreachable for a retail plan); fractions available in plans